Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

• US 9,908,920 B2
• Filed: 08/05/2016
• Issued: 03/06/2018
• Est. Priority Date: 08/05/2015
• Status: Active Grant

• Current Assignee: Immatics Biotechnologies GmbH (Immatics NV)
• Original Assignee: Immatics Biotechnologies GmbH (Immatics NV)
• Inventors: Mahr, Andrea, Weinschenk, Toni, Schoor, Oliver, Fritsche, Jens, Singh, Harpreet, Mueller, Phillip, Leibold, Julia, Goldfinger, Valentina
• Primary Examiner(s): Huff, Sheela J.
• Application Number:
  US15/229,970
• Publication Number:
  US 20170037089A1
• Time in Patent Office: 578 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 5/0636 T lymphocytes
• CPC Class Codes: C12N 5/0639 Dendritic cells, e.g. Langherhans cells in the epidermis
• CPC Class Codes: C12N 9/6445 Kallikreins (3.4.21.34; 3.4.21.35)
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 : Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 : Expression markers
• CPC Class Codes: C12Q 2600/16 : Primer sets for multiplex assays
• CPC Class Codes: G01N 2570/00 : Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
• CPC Class Codes: G01N 2800/52 : Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57407 : Specifically defined cancers
• CPC Class Codes: G01N 33/5748 : involving oncogenic proteins
• CPC Class Codes: G01N 33/6848 : Methods of protein analysis involving mass spectrometry

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claims

1. An antibody that specifically binds to a peptide consisting of the amino acid sequence of ALLTFVWKL (SEQ ID NO:

4) or binds to a peptide consisting of the amino acid sequence of ALLTFVWKL (SEQ ID NO;

     4) complexed with an MHC molecule.

2. A kit comprising:

(a) a container comprising a pharmaceutical composition containing the antibody of claim 1 in solution or in lyophilized form;

(b) optionally, a second container containing a diluent or reconstituting solution for the lyophilized formulation;

(c) optionally, the peptide having the amino acid sequence of ALLTFVWKL (SEQ ID NO;

     4), and

(d) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.

3. The kit according to claim 2, further comprising one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe.

4. A pharmaceutical composition comprising

the antibody of claim 1 and a pharmaceutically acceptable carrier, and optionally, pharmaceutically acceptable excipients and/or stabilizers.

5. The antibody of claim 1, wherein said antibody is a polyclonal antibody, a monoclonal antibody, a bi-specific antibody or a chimeric antibody.

6. The antibody of claim 1, wherein the peptide bound to an MEW molecule is present in a tumor cell.

7. The antibody of claim 6, wherein the tumor cell is at least one selected from the group consisting of lung cancer, kidney cancer, brain cancer, stomach cancer, colon or rectal cancer, liver cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma (MCC), melanoma, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, gall bladder cancer, and bile duct cancer, and other tumors that show an overexpression of a protein comprising a peptide having the amino acid sequence of ALLTFVWKL (SEQ ID NO:

4).

8. The antibody of claim 6, wherein the tumor cell is prostate cancer.

9. The antibody of claim 1, wherein the antibody is labeled with a toxin.

10. The antibody of claim 1, wherein the antibody is labeled with a radionucleotide.

11. The antibody of claim 10, wherein the radionucleotide is ¹¹¹In, ⁹⁹Tc, ¹⁴C, ¹³¹C, ³H, ³²P, or ³⁵S.

12. The antibody of claim 1, wherein the affinity value (Kd) of the antibody is less than 1×

10 μ

M.

13. The antibody of claim 1, wherein the MEW is a MEW class I molecule.

14. The antibody of claim 1, wherein the MEW is a MEW class II molecule.

15. The antibody of claim 1, further comprising a binding affinity of below 20 nanomolar.

16. The antibody of claim 1, wherein the antibody is humanized.

17. The composition of claim 4, wherein the pharmaceutically acceptable carrier is saline, Ringer'"'"'s solution, dextrose solution, and/or solid hydrophobic polymer.

18. The composition of claim 17, wherein the solid hydrophobic polymer is film, liposome, or microparticle.

19. A pharmaceutical composition comprising the antibody of claim 6 and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising the antibody of claim 10 and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier.